GSK's Open Lab Looking To Synch Big Pharma Neglected Disease Initiatives
This article was originally published in PharmAsia News
Executive Summary
TOKYO - GlaxoSmithKline is making rounds to draw big pharma partners to its patent pool and open laboratory for neglected disease research, but questions linger over what will happen if precompetitive collaboration produces technology or compounds that have use outside of the world's poorest countries
You may also be interested in...
Big Pharma To Invest More On NCD Partnerships Over Next Decade – IFPMA Report
Although Big Pharma is investing more in partnerships related to non-communicable diseases such as cancer and diabetes, gaps remain in tech transfer activities and local solutions in developing nations where NCDs are on the rise.
Big Pharma More Willing To Cooperate On Neglected Disease Research But Funding Models Still Unclear
HONG KONG - Debate over how best to fund research and development of neglected diseases may be reshaped by changing patterns of cooperation among Big Pharma and non-industry groups
Big Pharma More Willing To Cooperate On Neglected Disease Research But Funding Models Still Unclear
HONG KONG - Debate over how best to fund research and development of neglected diseases may be reshaped by changing patterns of cooperation among Big Pharma and non-industry groups